Cero Therapeutics Holdings, Inc. Announces 2024 Special Meeting of Stockholders
Ticker: CEROW · Form: DEF 14A · Filed: Apr 15, 2024 · CIK: 1870404
Sentiment: neutral
Topics: Proxy Statement, Special Meeting, Cero Therapeutics, Stockholders, Virtual Meeting
TL;DR
<b>Cero Therapeutics Holdings, Inc. is holding its 2024 Special Meeting of Stockholders virtually on April 30, 2024.</b>
AI Summary
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. The 2024 Special Meeting of Stockholders for Cero Therapeutics Holdings, Inc. will be held virtually on April 30, 2024, at 5:00 p.m. Eastern Time. Stockholders of record as of March 20, 2024, are entitled to vote at the meeting. The proxy statement and proxy card are being made available on or about April 15, 2024. The company is formerly known as Phoenix Biotech Acquisition Corp., with a name change effective June 30, 2021. The filing is a Definitive Proxy Statement (DEF 14A) under the 1934 Act.
Why It Matters
For investors and stakeholders tracking CERO THERAPEUTICS HOLDINGS, INC., this filing contains several important signals. This filing is a routine proxy statement, indicating the company is seeking shareholder approval or providing information for an upcoming meeting, which is standard for publicly traded companies. The virtual format for the meeting suggests a move towards modern, accessible shareholder engagement, potentially reducing costs associated with physical meetings.
Risk Assessment
Risk Level: low — CERO THERAPEUTICS HOLDINGS, INC. shows low risk based on this filing. The filing is a routine proxy statement for a special meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Review the proxy statement to understand the proposals to be voted on at the special meeting and consider voting your shares.
Key Numbers
- 2024-04-30 — Special Meeting Date (Cero Therapeutics Holdings, Inc. 2024 Special Meeting of Stockholders)
- 5:00 p.m. Eastern Time — Special Meeting Time (Cero Therapeutics Holdings, Inc. 2024 Special Meeting of Stockholders)
- 2024-03-20 — Record Date (Stockholders of record on this date are entitled to vote)
- 2024-04-15 — Proxy Material Availability Date (Proxy Statement and Proxy Card first made available)
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- CERo (company) — Abbreviated company name
- Brian G. Atwood (person) — Chairman, Chief Executive Officer and Director
- Phoenix Biotech Acquisition Corp. (company) — Former company name
- 201 Haskins Way, Suite 230 South San Francisco, CA 94080 (location) — Company address
- April 30, 2024 (date) — Date of Special Meeting
- March 20, 2024 (date) — Record date for voting eligibility
- April 15, 2024 (date) — Date proxy materials are made available
FAQ
When did CERO THERAPEUTICS HOLDINGS, INC. file this DEF 14A?
CERO THERAPEUTICS HOLDINGS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 15, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by CERO THERAPEUTICS HOLDINGS, INC. (CEROW).
Where can I read the original DEF 14A filing from CERO THERAPEUTICS HOLDINGS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by CERO THERAPEUTICS HOLDINGS, INC..
What are the key takeaways from CERO THERAPEUTICS HOLDINGS, INC.'s DEF 14A?
CERO THERAPEUTICS HOLDINGS, INC. filed this DEF 14A on April 15, 2024. Key takeaways: The 2024 Special Meeting of Stockholders for Cero Therapeutics Holdings, Inc. will be held virtually on April 30, 2024, at 5:00 p.m. Eastern Time.. Stockholders of record as of March 20, 2024, are entitled to vote at the meeting.. The proxy statement and proxy card are being made available on or about April 15, 2024..
Is CERO THERAPEUTICS HOLDINGS, INC. a risky investment based on this filing?
Based on this DEF 14A, CERO THERAPEUTICS HOLDINGS, INC. presents a relatively low-risk profile. The filing is a routine proxy statement for a special meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading CERO THERAPEUTICS HOLDINGS, INC.'s DEF 14A?
Review the proxy statement to understand the proposals to be voted on at the special meeting and consider voting your shares. The overall sentiment from this filing is neutral.
How does CERO THERAPEUTICS HOLDINGS, INC. compare to its industry peers?
Cero Therapeutics Holdings, Inc. operates in the biotechnology sector, focusing on biological products.
Are there regulatory concerns for CERO THERAPEUTICS HOLDINGS, INC.?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.
Industry Context
Cero Therapeutics Holdings, Inc. operates in the biotechnology sector, focusing on biological products.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on.
- Ensure you are a stockholder of record by March 20, 2024, to be eligible to vote.
- Vote your shares prior to or during the virtual special meeting on April 30, 2024.
Year-Over-Year Comparison
This is a DEF 14A filing, a Definitive Proxy Statement, which is a standard disclosure for upcoming shareholder meetings. No prior filing of this type for this specific meeting is indicated.
Filing Stats: 4,461 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-04-15 16:36:27
Key Financial Figures
- $0.0001 — es of the Company’s common stock, $0.0001 par value per share (the “Common
Filing Documents
- ea0203708-def14a_cerothera.htm (DEF 14A) — 520KB
- image_001.jpg (GRAPHIC) — 3KB
- image_002.jpg (GRAPHIC) — 553KB
- image_003.jpg (GRAPHIC) — 351KB
- 0001213900-24-032997.txt ( ) — 1772KB
From the Filing
DEF 14A 1 ea0203708-def14a_cerothera.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 CERO THERAPEUTICS HOLDINGS, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. CERO THERAPEUTICS HOLDINGS, INC. 201 Haskins Way, Suite 230 South San Francisco, CA 94080 2024 SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 30, 2024 April 15, 2024 Dear Stockholders: We are pleased to invite you to attend the 2024 Special Meeting of Stockholders (the “Special Meeting”) of CERo Therapeutics Holdings, Inc. (the “Company” or “CERo”), which will be held at 5:00 p.m., Eastern Time, on April 30, 2024. The Special Meeting will be held in virtual meeting format only. You may attend the Special Meeting, submit questions and vote your shares electronically during the Special Meeting by visiting: https://www.cstproxy.com/cero/sm2024 Details regarding the business to be conducted at the Special Meeting are more fully described in the accompanying proxy statement for the 2024 Special Meeting (the “proxy statement”). Other than the proposals described in the proxy statement, the Company’s board of directors (the “Board”) is not aware of any other matters to be presented for a vote at the Special Meeting. Your vote is important . Whether or not you plan to virtually attend the Special Meeting, we encourage you to vote as soon as possible to ensure that your shares are represented. Information about voting methods is set forth in the accompanying proxy statement. Only CERo stockholders of record at the close of business on March 20, 2024 will be entitled to vote at the Special Meeting and any adjournment or postponement hereof. On behalf of the Company, thank you for your continued support. Sincerely, /s/ Brian G. Atwood Brian G. Atwood Chairman, Chief Executive Officer and Director THIS PROXY STATEMENT AND ENCLOSED PROXY CARD ARE FIRST BEING MADE AVAILABLE ON OR ABOUT APRIL 15, 2024. CERO THERAPEUTICS HOLDINGS, INC. 201 Haskins Way, Suite 230 South San Francisco, CA 94080 NOTICE OF 2024 SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 30, 2024 Dear Stockholders: NOTICE IS HEREBY GIVEN that the 2024 Special Meeting of Stockholders of CERo Therapeutics Holdings, Inc. (the “Company” or “CERo”) will be held on April 30, 2024, at 5:00 p.m. Eastern Time. The Special Meeting will be held in a virtual meeting format only. We are holding the meeting for the purpose of considering and acting upon: 1. The ratification of the appointment of Wolf & Company, P.C. (“Wolf”), as the Company’s independent registered public accounting firm for the 2024 fiscal year; 2. The approval, subject to certain conditions, of the issuance of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Series B convertible preferred stock, par value $0.0001 per share (“Series B Preferred Stock”), (iii) the exercise of warrants to purchase Common Stock (the “Common Warrants”) and (iv) the exercise of warrants to purchase 2,500 shares of Series A Preferred Stock (the “Preferred Warrants” and, together with the Common Warrants, the “PIPE Warrants”) and conversion of the underlying Series A Preferred Stock; 3. The approval, subject to certain conditions, of the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined below); 4. The approval of the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “Plan”), as amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shares; and 5. The approval of an adjournment of the Special Meeting, i